Answers are grounded in this paper and cite their sources.
Background: Establishing the concordance of commercially available PD-L1 assays and scoring algorithms in HNSCC is essential to understand potential differences in selected patient populations in the clinic and in immunotherapy clinical trials.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: